Nuwellis raises $3.4M via direct stock offering and $3.1M from warrant exercises

Study finds epoprostenol safe as alternative anticoagulant for pediatric Aquadex therapy, no bleeding events observed

Nuwellis announced a new peer-reviewed study in Frontiers in Pediatrics showing epoprostenol as a safe alternative anticoagulant during Aquadex ultrafiltration therapy in critically ill children. The retrospective study of 46 pediatric patients found...